UBS Asset Management slashes Abcellera Biologics stake by 43%

UBS Asset Management Americas LLC reduced its holding in Abcellera Biologics Inc. by 43.0% during the second quarter. The firm sold more than 3.25 million shares according to a recent SEC filing.

UBS now retains approximately 4.32 million shares. This position represents about 1.41% of the company.

Total institutional ownership currently stands at 61.42%. BlackRock and Bank of America recently established new positions in the company.